Taurine Supplementation Lowers Blood Pressure and Improves Vascular Function in Prehypertension Randomized, Double-Blind, Placebo-Controlled Study
Taurine Supplementation Lowers Blood Pressure and Improves Vascular Function in Prehypertension Randomized, Double-Blind, Placebo-Controlled Study
复制标题
在高血压前期随机、双盲、安慰剂对照研究中，补充牛磺酸可降低血压并改善血管功能
DOI：
10.1161/hypertensionaha.115.06624
复制
发表时间：
2016-03-01
期刊：
影响因子：
8.3
通讯作者：
Zhu, Zhiming
中科院分区：
文献类型：
--
作者：
Sun, Qianqian;Wang, Bin;Zhu, Zhiming
牛磺酸是最丰富的半必需含硫氨基酸，在高血压动物模型中具有降低血压的作用。然而，没有严格的临床试验已经验证了牛磺酸的这种有益作用是否发生在人类高血压或高血压前期，高血压发展的关键阶段。在这项随机、双盲、安慰剂对照研究中，我们评估了牛磺酸干预对高血压前期血压和血管功能的影响。我们将120名符合条件的高血压前期患者随机分配接受牛磺酸补充剂（每天1.6 g）或安慰剂治疗12周。补充牛磺酸可显著降低临床和24小时动态血压，尤其是正常高血压患者。牛磺酸/安慰剂的平均门诊收缩压下降幅度为7.2/2.6 mmHg，舒张压下降幅度为4.7/1.3 mmHg。牛磺酸/安慰剂组的平均动态收缩压降低为3.8/0.3 mmHg，舒张压降低为3.5/0.6 mmHg。此外，牛磺酸补充显着改善内皮依赖性和内皮非依赖性血管舒张和增加血浆硫化氢和牛磺酸浓度。此外，在牛磺酸治疗的高血压前期个体中，血压的变化与血浆H2S和牛磺酸水平呈负相关。为了进一步阐明其作用机制，进行了体内和体外实验研究。结果表明，牛磺酸处理通过抑制人和小鼠肠系膜动脉中瞬时受体电位通道亚型3介导的钙内流，上调硫化氢合成酶的表达，并降低激动剂诱导的血管反应性。总之，长期补充牛磺酸的降压效果显示出通过改善血管功能治疗高血压前期的前景。
Taurine, the most abundant, semiessential, sulfur-containing amino acid, is well known to lower blood pressure (BP) in hypertensive animal models. However, no rigorous clinical trial has validated whether this beneficial effect of taurine occurs in human hypertension or prehypertension, a key stage in the development of hypertension. In this randomized, double-blind, placebo-controlled study, we assessed the effects of taurine intervention on BP and vascular function in prehypertension. We randomly assigned 120 eligible prehypertensive individuals to receive either taurine supplementation (1.6 g per day) or a placebo for 12 weeks. Taurine supplementation significantly decreased the clinic and 24-hour ambulatory BPs, especially in those with high-normal BP. Mean clinic systolic BP reduction for taurine/placebo was 7.2/2.6 mmHg, and diastolic BP was 4.7/1.3 mmHg. Mean ambulatory systolic BP reduction for taurine/placebo was 3.8/0.3 mmHg, and diastolic BP was 3.5/0.6 mmHg. In addition, taurine supplementation significantly improved endothelium-dependent and endothelium-independent vasodilation and increased plasma H2S and taurine concentrations. Furthermore, changes in BP were negatively correlated with both the plasma H2S and taurine levels in taurine-treated prehypertensive individuals. To further elucidate the hypotensive mechanism, experimental studies were performed both in vivo and in vitro. The results showed that taurine treatment upregulated the expression of hydrogen sulfide-synthesizing enzymes and reduced agonist-induced vascular reactivity through the inhibition of transient receptor potential channel subtype 3-mediated calcium influx in human and mouse mesenteric arteries. In conclusion, the antihypertensive effect of chronic taurine supplementation shows promise in the treatment of prehypertension through improvement of vascular function.